H.C. Wainwright reiterates BridgeBio stock rating on patent case developments

BridgeBio Pharma remains in analysts’ favor, with H.C. Wainwright reiterating a Buy and $100 target while the stock trades at $73.28, up 102% over the past year. The key catalyst is Pfizer’s patent litigation over tafamidis/Vyndamax, where a settlement could push U.S. generic competition into the early 2030s instead of late 2028. Analyst sentiment around BridgeBio is broadly bullish, with consensus targets reaching as high as $157 and several firms citing Attruby and pipeline progress.

Analysis

The market is starting to price a longer-than-expected monopoly window in tafamidis, and the second-order winner is not just BridgeBio but the entire class of near-term ATTR-CM pricing power. If Pfizer can engineer a broad settlement that pushes generic entry out several years, it raises the implied terminal value of every incumbent therapy with a similar mechanism, because payers will have less leverage to demand concessions in the category. The market is still underestimating how much a delayed generic clock can support both volume durability and net price stability for BBIO’s product mix over the next 12-24 months.

For PFE, this is less about the lost product economics and more about signaling: a settlement that protects the branded franchise likely trades near-term legal certainty for a slower erosion curve, which can be valuation-neutral to slightly positive if the market was discounting a faster cliff. The bigger risk is that any comprehensive deal also normalizes a playbook for follow-on disputes, encouraging copycat settlement pressure across other high-margin specialty assets. That matters because even modest litigation outcomes can shift investor expectations for patent defensibility in the broader cardio-rare disease franchise.

The consensus looks too linear on BBIO. If Attruby uptake is already beating estimates, then the real optionality is not just a better quarter but a re-rating of durable operating leverage if generic tafamidis remains boxed out into the early 2030s. The contrarian risk is that the Street is extrapolating legal delay into permanent pricing power; payers can still respond with prior auth tightening, formulary exclusions, or step-edits, which would blunt the upside even if the patent calendar moves in BBIO’s favor.

Key Decisions for Investors

• Stay long BBIO into earnings with a 1-3 month horizon; the setup is asymmetric if revenue beats pair with favorable tafamidis litigation headlines. Use a trailing stop below the post-runup support zone because the stock has already rerated sharply and any payer pushback could unwind momentum quickly.
• For options, consider BBIO call spreads expiring after the next catalyst window; the thesis is legal-duration extension plus operating beat, but capped upside makes defined-risk structures preferable after a 100%+ one-year move.
• For PFE, avoid chasing on the headline: the trade is more of a volatility event than a clean directional long. If you want exposure, use a short-dated put spread only if the market begins to price a sharper exclusivity loss than the settlement scenario implies.
• Relative value: long BBIO / short a diversified large-cap pharma basket over 1-2 quarters. The long leg has idiosyncratic legal and launch upside, while the short leg hedges market beta and isolates the re-rating from extended specialty patent protection.
• Watch for any broad settlement language next week in Delaware; if it implies generic entry no earlier than 2031-2032, add to BBIO on the first pullback rather than the initial spike, since the market will likely need a digestion period before repricing peak-sales durability.